Evidence map›Paper›PMID 42490225›Full record

ArticleSTAR protocols2026

Simultaneous measurement of target and effector cell death, apoptosis, and proliferation in cell therapy development using flow cytometry.

Kristian Thomson, Kendra Klatt, Niklas Engels, Camille Dourlens, Daniel Schäfer, Melissa Quadflieg, Hannah Johanssen, Raphael Koch, Jürgen Wienands, Gerald Wulf

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in STAR protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kristian ThomsonClinic for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Lower Saxony 37075, Germany; Institute for Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Lower Saxony 37073, Germany. Electronic address: kristian.thomson@med.uni-goettingen.de.
Kendra KlattClinic for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Lower Saxony 37075, Germany.
Niklas EngelsInstitute for Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Lower Saxony 37073, Germany.
Camille DourlensClinic for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Lower Saxony 37075, Germany; Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, North Rhine-Westphalia 51429, Germany; Translational Molecular Imaging Group, Max-Planck Institute for Multidisciplinary Sciences, Göttingen, Lower Saxony 37075, Germany.
Daniel SchäferMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, North Rhine-Westphalia 51429, Germany.
Melissa QuadfliegMiltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, North Rhine-Westphalia 51429, Germany.
Hannah JohanssenClinic for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Lower Saxony 37075, Germany.
Raphael KochClinic for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Lower Saxony 37075, Germany.
Jürgen WienandsInstitute for Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Lower Saxony 37073, Germany.
Gerald WulfClinic for Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Lower Saxony 37075, Germany. Electronic address: gerald.wulf@med.uni-goettingen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of cellular immunotherapies against cancer requires an efficient assessment of malignant target cell killing. However, the fate of effector cells is equally important, particularly in the context of immunomodulatory tumors. Here, we present a high-throughput protocol for simultaneously measuring viability, apoptosis, and proliferation of cytotoxic effector cells and their targets. We describe steps for co-culturing target and effector cells, staining procedures for viability and apoptosis, adding fluorescent counting beads for cell quantification, and procedures for flow-cytometric analysis.

Indexed as

CancerCell BiologyHealth SciencesHigh Throughput ScreeningImmunology

Identifiers

PMID42490225
PMCPMC13427446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.